-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC30 subcutaneous (SQ) injection showed...
SINGAPORE, Jan. 13, 2025 /PRNewswire/ -- Luzerne Pte Ltd is proud to announce its crucial role in helping the Dehua Ceramic Trade Association (China)...
HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Gianna Lullume, an innovative brand committed to improving infant sleep and promoting family well-being, is proud to...
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc....
SHENZHEN, China, Jan. 13, 2025 /PRNewswire/ -- Addentax Group Corp. ("Addentax" or the "Company") (Nasdaq: ATXG), an integrated service provider focusing on garment manufacturing,...
- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine
- Based on the Excellent Safety and Immune Response in...